# US 2026/0125647 A1 · Age-modulating compounds and methods for making age-modulated cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0125647 A1
- Document ID: US20260125647A1
- Status: Published application
- Kind: A1
- Application number: 19/438,959
- Filed: 2026-01-02
- Published: 2026-05-07
- Earliest claimed: 2023-07-03
- Assignees: Memorial Sloan Kettering Cancer Center; Memorial Hospital for Cancer and Allied Diseases; Sloan-Kettering Institute for Cancer Research
- Applicants: Memorial Sloan-Kettering Cancer Center; Memorial Hospital for Cancer and Allied Diseases; Sloan-Kettering Institute for Cancer Research
- Inventors: Nathalie SAURAT; Lorenz Studer
- Web page: https://patentgrep.com/patent/US20260125647A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C12N 5/0656: {Adult fibroblasts}
- A61K 31/05: Phenols {(cannabinoids A61K31/658)}
- A61K 31/136: having the amino group directly attached to the aromatic ring, e.g. benzeneamine
- A61K 31/365: Lactones
- A61K 31/453: containing a six-membered ring with oxygen as a ring hetero atom
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/475: having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine (vincamine A61K31/4375)
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/7064: containing condensed or non-condensed pyrimidines
- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 5/0619: {Neurons}
- C12N 2501/065: Modulators of histone acetylation
- C12N 2501/405: Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases
- C12N 2501/81: Adrenaline
- C12N 2503/02: Drug screening
- C12N 2506/1307: from adult fibroblasts
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are age-modulated cells and method for making age-modulated cells. The aging and rejuvenation processes can be induced for young, aged, mature and/or immature cells, such as a somatic cell, a stem cell, a stem cell-derived somatic cell, including an induced pluripotent stem cell-derived cell, by contacting cells with one or more age-inducing or rejuvenating agent. Methods described by the present disclosure can produce age-appropriate cells from a somatic cell or a stem cell, such as an old cell, young cell, immature cell, and/or a mature cell. Such age-modified cells constitute model systems for the study of late-onset diseases and/or disorders.

## Claims

### Claim 1

A method for inducing cellular aging in a cell or population of cells, comprising contacting the cell or population of cells with one or more age-inducing agent.

### Claim 2 (depends on 1)

The method of claim 1, wherein the cell or population of cells comprise fibroblasts; wherein the one or more age-inducing agent is selected from the group consisting of one or more cyclin-dependent kinase (CDK) inhibitor, one or more adenosine kinase inhibitor, one or more topoisomerase II inhibitor, one or more protein kinase C (PKC) inhibitor, one or more DNA binding agent, and any combination thereof.

### Claim 3 (depends on 2)

The method of claim 2, wherein:
a. the one or more CDK inhibitor comprises alvocidib;
b. the one or more adenosine kinase inhibitor comprises 5-iodotubercin;
c. the one or more topoisomerase II inhibitor comprises mitoxantrone;
d. the one or more PKC inhibitor comprises bisindolylmaleimide-ix; and/or
e. the one or more DNA binding agent comprises chromomycin-a3.

### Claim 4 (depends on 1)

The method of claim 1, wherein the cell or population of cells comprise neurons, motoneurons, cortical neurons, peripheral sensory neurons, or midbrain dopamine neurons; wherein the one or more age-inducing agent is selected from the group consisting of one or more DNA synthesis inhibitor, one or more microtubule antagonist, one or more Sirtuin-2 (SIRT2) inhibitor, BRD-K25731886, doxercalciferol, and any combination thereof.

### Claim 5 (depends on 4)

The method of claim 4, wherein:
a) the one or more DNA synthesis inhibitor comprises fludarabine;
b) the one or more microtubule antagonist comprises vinorelbine; and/or
c) the one or more SIRT2 inhibitor comprises AGK2.

### Claim 6 (depends on 1)

The method claim 1, wherein the cell or population of cells are derived from primary cells, fetal cells, pluripotent stem cells, embryonic stem cells, induced pluripotent stem cells, or any combination thereof.

### Claim 7 (depends on 1)

The method of claim 1, wherein the cell or population of cells are human.

### Claim 8 (depends on 1)

The method of claim 1, wherein:
a) contacting the cell or population of cells with one or more age-inducing agent increases the expression level or presence in the cell or population of cells of one or more chronological marker signature of an old cell;
b) contacting the cell or population of cells with one or more age-inducing agent decreases the expression level or presence in the cell or population of cells of one or more chronological marker signature of a young cell; and/or
c) contacting the cell or population of cells with one or more age-inducing agent induces loss of heterochromatin, disrupted nuclear lamina, increased DNA damage, increased cellular senescence, disrupted proteostasis and increased dependence on autophagy, increased caveolin-1 (CAV1) expression, or any combination thereof.

### Claim 9

A method for rejuvenating cellular age in a cell or population of cells, comprising contacting the cell or population of cells with one or more rejuvenating agent.

### Claim 10 (depends on 9)

The method of claim 9, wherein the cell or population of cells comprise fibroblasts; wherein the one or more rejuvenating agent is selected from the group consisting of one or more histone deacetylase (HDAC) inhibitor, one or more heat shock protein (HSP) inhibitor, one or more adrenergic receptor antagonist, one or more phosphoinositide 3-kinase (PI3K) inhibitor, and any combination thereof.

### Claim 11 (depends on 10)

The method of claim 10, wherein:
a) the one or more HDAC inhibitor comprises mocetinostat;
b) the one or more HSP inhibitor comprises radicicol, geldanamycin, or a combination thereof;
c) the one or more adrenergic receptor antagonist comprises alfuzosin; and/or
d) the one or more PI3K inhibitor comprises wortmannin.

### Claim 12 (depends on 9)

The method of claim 9, wherein the cell or population of cells comprise neurons, motoneurons, cortical neurons, peripheral sensory neurons, or midbrain dopamine neurons; wherein the one or more rejuvenating agent is selected from the group consisting of one or more Sirtuin (SIRT) activator, one or more HDAC inhibitor, one or more poly ADP ribose polymerase (PARP) inhibitor, one or more ataxia telangiectasia and Rad3-related (ATR) signaling inhibitor, and any combination thereof.

### Claim 13 (depends on 12)

The method of claim 12, wherein:
a) the one or more SIRT activator comprises resveratrol;
b) the one or more HDAC inhibitor comprises SB-939, BRD-A19037878, or any combination thereof;
c) the PARP inhibitor comprises veliparib; and/or
d) the ATR signaling inhibitor comprises VE-821.

### Claim 14 (depends on 9)

The method of claim 9, wherein the cell or population of cells are derived from primary cells, fetal cells, pluripotent stem cells, embryonic stem cells, induced pluripotent stem cells, or any combination thereof.

### Claim 15 (depends on 9)

The method of claim 9, wherein the cell or population of cells are human.

### Claim 16 (depends on 9)

The method of claim 9, wherein:
a) contacting the cell or population of cells with one or more rejuvenating agent increases the expression level or presence in the cell or population of cells of one or more chronological marker signature of a young cell;
b) contacting the cell or population of cells with one or more rejuvenating agent decreases the expression level or presence in the cell or population of cells of one or more chronological marker signature of an old cell; and/or
c) contacting the cell or population of cells with one or more rejuvenating agent reduces loss of heterochromatin, disrupted nuclear lamina, DNA damage, cellular senescence, disrupted proteostasis and dependence on autophagy, caveolin-1 (CAV1) expression, or any combination thereof

### Claim 17

A method of modeling neurodegenerative disease, comprising:
contacting a cell or population of cells with one or more age-inducing agent to obtain an age-modulated cell or population of age-modulated cells; and
contacting the age-modulated cell or population of age-modulated cells with one or more candidate compound.

### Claim 18 (depends on 17)

The method of claim 17, further comprising detecting an alteration in at least one of the survival, biological activity, structure or morphology of the age-modulated cell or population of age-modulated cells.

### Claim 19 (depends on 18)

The method of claim 18, further comprising selecting as the drug a candidate one or more compound that alters at least one of the survival, biological activity, structure or morphology of the age-modulated cell or population of age-modulated cells.

### Claim 20 (depends on 17)

The method of claim 17, wherein the neurodegenerative disease is Parkinson's disease (PD) or Alzheimer's Disease (AD).
